Identification of cell cycle-targeting microRNAs through genome-wide screens

ABSTRACT By performing nine genome-wide microRNA (miRNA) screens, we recently uncovered a new class of miRNAs, which target multiple cyclins and cyclin-dependent kinases (CDKs). Systemic delivery of selected cell cycle-targeting miRNAs to mouse xenograft models resulted in potent anti-tumorigenic effects without affecting animals' health. Here, we provide an in-depth description of our miRNA screening methodology, analyses of selected cell cycle-targeting miRNAs, and discuss why miRNA therapy might be a viable therapeutic option for cancer patients.

• Publication year

  2017

• Venue

  Cell Cycle

• Publication date

  2017-11-14

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1080/15384101.2017.1380132PMID 29099267PMCID 5788471
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Nanocarriers for microRNA delivery in cancer medicine.

  2017cited by this paper
• Nanoparticles for immune system targeting.

  2017cited by this paper
• MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.

  2017cited by this paper
• MicroRNA therapeutics: towards a new era for the management of cancer and other diseases

  2017cited by this paper
• Cell-Cycle-Targeting MicroRNAs as Therapeutic Tools against Refractory Cancers.

  2017cited by this paper
• Palbociclib and Letrozole in Advanced Breast Cancer.

  2016cited by this paper
• Capsular vaso-mimicry formed by transgenic mammary tumor spheroids implanted ectopically into mouse dorsal skin fold: implications for cellular mechanisms of metastasis [version 2; peer review: 1 approved, 3 approved with reservations]

  2016cited by this paper
• Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors.

  2016cited by this paper
• Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatment

  2016cited by this paper
• Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.

  2016cited by this paper
• Predicting effective microRNA target sites in mammalian mRNAs

  2015cited by this paper
• The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.

  2015cited by this paper
• miRWalk2.0: a comprehensive atlas of microRNA-target interactions

  2015cited by this paper
• A Uniform System for the Annotation of Vertebrate microRNA Genes and the Evolution of the Human microRNAome.

  2015cited by this paper
• The history and future of targeting cyclin-dependent kinases in cancer therapy

  2015cited by this paper
• In vivo delivery of miRNAs for cancer therapy: challenges and strategies.

  2015cited by this paper
• Aberrant regulation and function of microRNAs in cancer.

  2014cited by this paper
• miRDB: an online resource for microRNA target prediction and functional annotations

  2014cited by this paper
• Global analyses of the effect of different cellular contexts on microRNA targeting.

  2014cited by this paper
• Clinical applications of microRNAs

  2013cited by this paper
• miR-15a and miR-16-1 downregulate CCND1 and induce apoptosis and cell cycle arrest in osteosarcoma.

  2012cited by this paper
• Therapeutic targeting of the cyclin D3:CDK4/6 complex in T cell leukemia.

  2012cited by this paper
• The requirement for cyclin D function in tumor maintenance.

  2012cited by this paper
• Cyclin D as a therapeutic target in cancer

  2011cited by this paper
• Weak Seed-Pairing Stability and High Target-Site Abundance Decrease the Proficiency of lsy-6 and Other miRNAs

  2011cited by this paper
• Expanding the microRNA targeting code: functional sites with centered pairing.

  2010cited by this paper
• A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma.

  2010cited by this paper
• Mammalian microRNAs: experimental evaluation of novel and previously annotated genes.

  2010cited by this paper
• Strategies in the design of nanoparticles for therapeutic applications

  2010cited by this paper
• TargetSpy: a supervised machine learning approach for microRNA target prediction

  2010cited by this paper
• Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes.

  2010cited by this paper
• Targeting microRNAs in cancer: rationale, strategies and challenges

  2010cited by this paper
• The landscape of somatic copy-number alteration across human cancers

  2010cited by this paper
• Lipid-like materials for low-dose, in vivo gene silencing

  2010cited by this paper
• Cdk2 suppresses cellular senescence induced by the c-myc oncogene

  2010cited by this paper
• MicroRNAs: Target Recognition and Regulatory Functions

  2009cited by this paper
• Widespread shortening of 3'UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells.

  2009cited by this paper
• miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer.

  2009cited by this paper
• DLEU2, frequently deleted in malignancy, functions as a critical host gene of the cell cycle inhibitory microRNAs miR-15a and miR-16-1.

  2009cited by this paper
• 3’UTR mediated regulation of the cyclin D1 proto-oncogene

  2009cited by this paper
• Cell cycle, CDKs and cancer: a changing paradigm

  2009cited by this paper
• Proliferating Cells Express mRNAs with Shortened 3' Untranslated Regions and Fewer MicroRNA Target Sites

  2008cited by this paper
• The miR-15a–miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities

  2008cited by this paper
• Most mammalian mRNAs are conserved targets of microRNAs.

  2008cited by this paper
• miR-16 family induces cell cycle arrest by regulating multiple cell cycle genes

  2008cited by this paper
• Cdk2 deficiency decreases ras/CDK4-dependent malignant progression, but not myc-induced tumorigenesis.

  2007cited by this paper
• Distinct pathways of genomic progression to benign and malignant tumors of the liver

  2007cited by this paper
• MicroRNA targeting specificity in mammals: determinants beyond seed pairing.

  2007cited by this paper
• Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis.

  2006cited by this paper
• Requirement for CDK4 kinase function in breast cancer.

  2006cited by this paper
• Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets.

  2005cited by this paper
• Cyclins and cdks in development and cancer: a perspective

  2005cited by this paper
• Cancer nanotechnology: opportunities and challenges

  2005cited by this paper
• Living with or without cyclins and cyclin-dependent kinases.

  2004cited by this paper
• Minireview: Cyclin D1: normal and abnormal functions.

  2004cited by this paper
• Requirement for cyclin D3 in lymphocyte development and T cell leukemias.

  2003cited by this paper
• MicroRNA targets in Drosophila

  2003cited by this paper
• MicroRNA Targets in Drosophila

  2003cited by this paper
• Cycling to Cancer with Cyclin D1

  2002cited by this paper
• Specific protection against breast cancers by cyclin D1 ablation

  2001cited by this paper
• Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells.

  1999cited by this paper
• The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway.

  1999cited by this paper

• Deregulated cell cycle control: The interplay between non-coding RNAs and cyclin-dependent kinases in tumorigenesis.

  2025cites this paper
• Concepts and Design of Introducing Synthetic MicroRNAs into Mammalian Cells.

  2022cites this paper
• Construction of a Full-Length 3'UTR Reporter System for Identification of Cell-Cycle Regulating MicroRNAs.

  2021cites this paper
• PCAT1 induced by transcription factor YY1 promotes cholangiocarcinoma proliferation, migration and invasion by sponging miR-216a-3p to up-regulate oncogene BCL3.

  2021cites this paper
• Elevated expression of miR-494-3p is associated with resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer

  2021cites this paper
• PCAT1 induced by transcription factor YY1 promotes cholangiocarcinoma proliferation, migration and invasion by sponging miR-216a-3p to up-regulate oncogene BCL3

  2020cites this paper
• miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC.

  2019cites this paper
• miR-126-5p targets Malate Dehydrogenase 1 in non-small cell lung carcinomas.

  2018cites this paper